Kintor Pharmaceutical Ltd. received an emergency use authorization (EUA) for proxalutamide in the treatment of COVID-19 in Paraguay. There has been a great deal of skepticism over the too-good-to-be-true early results from this drug. There have been some questions over the quality of the data and biases too. Based on only 25 patients, the action seems like paltry data to justify an EUA. As TrialSite has shared, drug manufacturers' press releases always paint the most optimistic picture possible. However, Paraguay is under assault from the Lamba variant with one of the highest new deaths per capita rate (7.83/1m). Therefore, they are desperate. Perhaps this leans more toward a real-world-evidence (RWE) experiment for this therapeutic? The evidence will be apparent over time.
Also known as GT-0918, this nonsteroidal antiandrogen (NSAA)—specifically, a selective high-affinity salient antagonist of the androgen receptor (AR) actually developed a subsidiary of Kintor called Suzhou Kintor Pharmaceuticals, Inc. for the treatment of COVID-19, prostate cancer, and breast cancer.
The nation is also aggressively pursuing a vaccination campaign with recent l...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).